Rgenta

Rgenta develops RNA-based therapeutics for neurological disorders, oncology, and other diseases. The company builds compound libraries designed to recognize RNA target sites and modulate their function, particularly those mediated by regulatory proteins. Its data-driven mRNA target identification platform accounts for cell type-specific target regulation and predicts the biological consequences of target modulation, enabling systematic discovery of small molecules that target RNA. Founded in 2018 and headquartered in Cambridge, United States, Rgenta has raised $90M in Series A funding from investors including Boehringer Ingelheim Venture Fund, AstraZeneca, Matrix Partners China, Lilly Asia Ventures, Vivo Capital, Kaitai Capital, Korea Investment Partners, and EQT. The company's approach opens new therapeutic possibilities by targeting previously undruggable RNA structures, expanding the druggable genome beyond protein targets.